ENDRA Life Sciences Inc (NASDAQ:NDRA) Director Michael Harsh bought 9,500 shares of ENDRA Life Sciences stock in a transaction on Friday, June 7th. The shares were purchased at an average cost of $1.11 per share, for a total transaction of $10,545.00. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of NASDAQ NDRA traded up $0.23 during mid-day trading on Thursday, hitting $1.46. The company had a trading volume of 498,421 shares, compared to its average volume of 120,511. ENDRA Life Sciences Inc has a 12 month low of $0.90 and a 12 month high of $5.75.
ENDRA Life Sciences (NASDAQ:NDRA) last announced its quarterly earnings results on Monday, March 11th. The company reported ($0.28) earnings per share (EPS) for the quarter.
A number of research firms have commented on NDRA. Dougherty & Co started coverage on ENDRA Life Sciences in a report on Thursday. They set a “buy” rating on the stock. Lake Street Capital started coverage on ENDRA Life Sciences in a report on Monday, May 20th. They issued a “buy” rating on the stock.
About ENDRA Life Sciences
ENDRA Life Sciences Inc develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding.
See Also: Put Option Volume
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.